1. Pink Sheet
  2. >>Market Access

The COVID-19 Effect: Medicare Part B Oncology Drug Claims Down 40% Through April

 
• By Cathy Kelly

Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.

Infusion of a hospital
Physician Administration Of Infused Drugs Down Sharply

Medicare Part B claims for the top 10 oncology drugs in terms of spending were significantly lower at the end of April compared to the previous year as the COVID-19 pandemic limited patient access to in-person care, according to a recent analysis by Avalere Health.

Avalere looked at billing frequency for branded oncology drugs (including chemotherapies and immune-oncology) with the highest Part B drug spending...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Sanofi Secures EU Fast-Track Status For ‘Game-Changing’ Sleeping Sickness Drug

 
• By Neena Brizmohun

If approved, Sanofi’s acoziborole could become the first single-dose oral treatment for sleeping sickness.

Mexico Speeds Up Market Access With Regulatory Reliance Guidelines

 
• By Francesca Bruce

Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther

Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.